HPLC-MS/MS法测定人血浆中的左西孟旦及其主要代谢物

建立快速、 灵敏、 易操作的LC-MS/MS法测定人血浆中的左西孟旦及其代谢物OR-1855和OR-1896的浓度。根据待测物的不同性质， 采用两套液相色谱系统和电离方式分别测定人血浆中的左西孟旦和代谢物OR-1855、 OR-1896。测定左西孟旦时， 用瑞舒伐他汀为内标， 血浆样品经甲醇沉淀蛋白， 以甲醇-15 mmol·L^-1醋酸铵-甲酸(55∶45∶0.02， v/v/v)为流动相， Capcell MG III C₁₈柱(35 mm×2.0 mm ID， 3 μm)进行分离， 采用电喷雾电离源，以选择反应监测(SRM)方式进行负离子检测。测定代谢物OR-1855和OR-1896时， 用多索茶碱为内标， 血浆样品经乙酸乙酯萃取， 以甲醇-15 mmol·L^-1醋酸铵-甲酸(65∶35∶0.1， v/v/v)为流动相， Zorbax Extend C₁₈柱(150 mm×4.6 mm ID， 5 μm)进行分离， 采用电喷雾电离源， SRM方式进行正离子检测。测定血浆中左西孟旦方法的线性范围为0.10～50.0 ng·mL^-1， 定量下限可达0.10 ng·mL^-1； 测定血浆中代谢物OR-1855和OR-1896方法的线性范围均为0.20～100 ng·mL^-1， 定量下限均可达0.20 ng·mL^-1。本方法专属性好， 准确、 快速， 适用于左西孟旦注射液的临床药代动力学研究。

Determination of levosimendan and its main metabolites in human plasma with HPLC-MS/MS method

This paper is aimed to develop rapid, sensitive and convenient HPLC-MS/MS methods for the quantification of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma. According to the different natures of the compounds, two sets of liquid chromatography and ionization modes were used for determination the concentration of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma, separately. Following protein precipitation with methanol, the levosimendan and internal standard (rosuvastatin) were separated on a Capcell MG III C₁₈ column (35 mm×2.0 mm ID, 3 μm) with the mobile phase consisted of methanol-15 mmol·L^-1 ammonium acetate-formic acid (55∶45∶0.02, v/v/v). A tandem mass spectrometer equipped with electrospray ionization source was used as the detector and operated in the negative ion mode. Its metabolites OR-1855, OR-1896 and internal standard doxofylline were extracted from plasma by liquid-liquid extraction with ethyl acetate. Chromatographic separation was performed on a Zorbax Extend C₁₈ column(150 mm×4.6 mm ID, 5 μm)with the mobile phase consisted of methanol-15 mmol·L^-1 ammonium acetate-formic acid (65∶35∶0.1, v/v/v). A tandem mass spectrometer equipped with electrospray ionization source was used as the detector and operated at the positive ion mode. The linear concentration ranges of the calibration curves for levosimendan and OR-1855 and OR-1896 were 0.10-50.0 ng·mL^-1, 0.20-100 ng·mL^-1, 0.20-100 ng·mL^-1, respectively. The lower limits of quantification of levosimendan and OR-1855 and OR-1896 were 0.10 ng·mL^-1, 0.20 ng·mL^-1, 0.20 ng·mL^-1, respectively. The methods proved to be sensitive, simple and rapid, and suitable for the pharmacokinetic study of levosimendan injection.